On October 21, the Utah Department of Health and Human Services (DHHS) released a bulletin to Utah medical cannabis patients regarding the detection of synthetic cannabinoids in state-sponsored medical cannabis sales. The DHHS now requires that if a medical cannabis product contains a synthetic or derivative ingredient, the label will include the following statement: “This product contains a derivative and/or synthetic cannabinoid.” But some advocates say it isn’t enough. Read the article here.
Utah medical cannabis flooded with synthetic cannabinoids from hot hemp
Click here to learn how STEM selects new articles.